Personalized Peptide-based Vaccination for Treatment of Colorectal Cancer: Rational and Progress

(E-pub Ahead of Print)

Author(s): Seyed Mostafa Parizadeh, Reza Jafarzadeh-Esfehani, Maryam Ghandehari, Afsaneh Rezaei-Kalat, Seyed Mohammad Reza Parizadeh, Afsane Javanbakht, Seyed Mahdi Hassanian, Gordon A. Ferns, Majid Khazaei, Amir Avan*.

Journal Name: Current Drug Targets

Become EABM
Become Reviewer

Abstract:

Colorectal cancer (CRC) is one of the most common cancers globally and is associated with a high rate of morbidity and mortality. A large proportion of patients with early stage CRC who undergo conventional treatments develop local recurrence or distant metastasis and in this group of advanced disease, the survival rate is low. Furthermore there is often a poor response and/or toxicity associated with chemotherapy and chemo-resistance may limit continuing conventional treatment alone. Choosing novel and targeted therapeutic approaches based on clinicopathological and molecular features of tumors in combination with conventional therapeutic approach could be used to eradicate residual micrometastasis and therefore improve patient prognosis and also be used preventively. Peptide-based vaccination therapy is one class of cancer treatment that could be used to induce tumor-specific immune responses, through the recognition of specific antigen-derived peptides in tumor cells, and this has emerged as a promising anti-cancer therapeutic strategy. The aim of this review was to summarize the main findings of recent studies in exciting field of peptide-based vaccination therapy in CRC patients as a novel therapeutic approach in treatment of CRC.

Keywords: Peptide, vaccine, immunotherapy, colorectal cancer, treatment

Rights & PermissionsPrintExport Cite as


Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1389450120666190619121658
Price: $95

Article Metrics

PDF: 3